Similar articles

• SEOM clinical guideline for secondary prevention (2019).

  Santaballa A, Pinto Á, Balanyà RP, Ramírez Merino N, Martín IR, Grau SS, Fombella JPB, Cano JM, González CH, Bayo J. Santaballa A, et al. Clin Transl Oncol. 2020 Feb;22(2):187-192. doi: 10.1007/s12094-020-02302-0. Epub 2020 Jan 31. Clin Transl Oncol. 2020. PMID: 32006339
• SEOM 2023 clinical guidelines.

  Montes AF, Rodríguez C. Montes AF, et al. Clin Transl Oncol. 2024 Nov;26(11):2755-2757. doi: 10.1007/s12094-024-03737-5. Epub 2024 Sep 26. Clin Transl Oncol. 2024. PMID: 39325264 No abstract available.
• SEOM clinical guidelines in advanced and recurrent breast cancer (2018).

  Chacón López-Muñiz JI, de la Cruz Merino L, Gavilá Gregori J, Martínez Dueñas E, Oliveira M, Seguí Palmer MA, Álvarez López I, Antolin Novoa S, Bellet Ezquerra M, López-Tarruella Cobo S. Chacón López-Muñiz JI, et al. Clin Transl Oncol. 2019 Jan;21(1):31-45. doi: 10.1007/s12094-018-02010-w. Epub 2019 Jan 8. Clin Transl Oncol. 2019. PMID: 30617924 Free PMC article.
• Clinical practice guidelines for the use of erythroid-stimulating agents: ASCO, EORTC, NCCN.

  Lichtin AE. Lichtin AE. Cancer Treat Res. 2011;157:239-48. doi: 10.1007/978-1-4419-7073-2_14. Cancer Treat Res. 2011. PMID: 21052960 Review. No abstract available.
• [Choosing wisely recommendations in hematology and oncology].

  Krause SW, Neubauer A. Krause SW, et al. Internist (Berl). 2017 Jun;58(6):545-549. doi: 10.1007/s00108-017-0249-5. Internist (Berl). 2017. PMID: 28497377 Review. German.